IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Biotechnology

Healthcare
$26.49 -1.45%

-$0.45 today

Market cap
$2.56B
Beta
-0.05
P/E (TTM)
-19.5
EPS (TTM)
-$1.58
52W Low $20.50High $39.28

Volume 1.45M

Average 1.44M

IDYA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

IDEAYA Biosciences, Inc.NASDAQ: IDYA

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin at 82.6%

Gross margin was 82.6% in Q1 FY2026. On a trailing-twelve-month basis it was -8.7%, up 943.2 pp year over year. Over 3 fiscal years it widened by 2.0 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
82.6%+778.8 pp QoQ
Last fiscal yearDec 2025
97.9%+52.7 pp YoY
LTMMar 2026
-8.7%+943.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year+52.7 pp——
3 years+2.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
97.9%
Year-over-year change
+52.7pp

Gross Margin vs competitors

How IDYA compares with its peers on the latest reported figures

  • IDYA's LTM Mar 2026 gross margin of -8.7% is the lowest of the 6 companies compared; the peer median is 86.5%.
  • Its year-over-year change of +943.2 pp is the highest of 6, against a peer median of -3.7 pp.
  • Over three fiscal years its change of +2.0 pp compares with a peer median of -7.2 pp.
IDYA Competitors Peer median
Gross Margin for IDYA and competitors
Company Period LTM level YoY 3-year change
PRLDPrelude Therapeutics IncorporatedLTM Mar 202697.7% -2.3 pp—
TNGXTango Therapeutics, Inc.FY202596.3% -3.7 pp-3.7 pp
NRIXNurix Therapeutics, Inc.LTM Aug 202686.5% +249.4 pp+455.2 pp
VSTMVerastem, Inc.LTM Mar 202683.7% -16.3 pp-17.1 pp
FHTXFoghorn Therapeutics Inc.LTM Mar 202622.3% -77.7 pp-10.8 pp
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-8.7% +943.2 pp+2.0 pp
RVMDRevolution Medicines, Inc.FY2025— ——
ERASErasca, Inc.FY2025— ——
COGTCogent Biosciences, Inc.FY2025— ——
Peer median (excluding IDYA) 86.5%-3.7 pp-7.2 pp

Competitors are the stored peer set for IDYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.94M50.93M23.39M7M218.71M
Cost of Revenue1.73M2.1M4.01M3.83M4.59M
Gross Profit26.22M48.83M19.38M3.17M214.12M
Gross Margin93.8%95.9%82.9%45.2%97.9%
Research & Development58.16M89.54M129.51M294.67M314.7M
Selling, General & Admin18.33M21.8M24.3M35.47M63.32M
Operating Expenses76.48M111.33M153.81M330.14M373.43M
Depreciation & Amortization1.73M2.1M4.01M3.83M4.59M
EBITDA(48.04M)(56.55M)(108.95M)(270.64M)(109.11M)
EBITDA Margin-171.9%-111.0%-465.9%-3866.3%-49.9%
Operating Income(50.27M)(62.5M)(134.43M)(326.98M)(159.31M)
Operating Margin-179.9%-122.7%-574.9%-4671.1%-72.8%
Interest Income506K3.85M21.47M52.5M45.62M
Interest Expense00000
Other Income / Expenses506K3.85M21.47M52.5M45.62M
Income Before Tax(49.76M)(58.66M)(112.96M)(274.48M)(113.7M)
Pre-Tax Margin-178.1%-115.2%-483.0%-3921.1%-52.0%
Income Tax Expense00000
Net Income(49.76M)(58.66M)(112.96M)(274.48M)(113.7M)
Net Margin-178.1%-115.2%-483.0%-3921.1%-52.0%
EPS (Basic)(1.41)(1.42)(1.96)(3.36)(1.28)
EPS (Diluted)(1.41)(1.42)(1.96)(3.36)(1.28)
Weighted Avg Shares35.25M41.44M57.52M81.68M88.49M
Weighted Avg Shares (Diluted)35.25M41.44M57.52M81.68M88.49M

IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Intrinsic Alpha fair value

Locked

Current Price

$26.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.